CATIE IMMUNOMODULATORS: Pentoxifylline (Trental)

DonateNow

IMMUNOMODULATORS: Pentoxifylline (Trental)

TreatmentUpdate40: February 1993
Sean Hosein


Studies of people infected with HIV have found that parts of the immune system are excessively stimulated while others are suppressed. One chemical produced by the immune system is TNF (tumour necrosis factor). People with HIV infection appear to produce high levels of TNF compared with healthy, non-HIV-infected subjects. Excessive levels of TNF may increase production of HIV and indirectly help to destroy T-cells. TNF may also be linked to the persistent weight loss seen in AIDS called the wasting syndrome. A number of agents which might reduce TNF levels have been proposed to test in people with HIV infection. One of those drugs is pentoxifylline (sold under the brand name Trental). Pentoxifylline has been used to improve blood circulation in humans. In laboratory experiments, the drug can increase the anti-HIV effect of ddI. We now report on results from experiments on people with HIV infection.

REFERENCES:

1. Chaldakov GN. An anti-tumour necrosis factor therapy. AIDS 1992;6(4):439- 440.


930201
CATI4007


ÆGIS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1993.

Copyright © 1993 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284  http://www.catie.ca


This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1993. AEGIS.